Search
State ActionCCAGW Urges Maine House of Representatives to Oppose LD 1550
CCAGW urges the Maine House of Representatives to oppose a ban on flavored tobacco products.
Letters to OfficialsCAGW Submits Comments to APPG Inquiry
CAGW expresses its support for the U.K.’s APPG for Vaping’s report on the upcoming WHO FCTC COP9 meeting
PressCAGW Releases Issue Brief on the Folly of Government-Owned Networks
Government-owned broadband networks are wasteful, anti-competitive, and costly for taxpayers.
Letters to OfficialsLetter to Senate Opposing the "Hotline" of S. 1435
S. 1435 is a bill that would amend the FTC Act with regard to pharmaceutical patents and “product hopping.”
The WasteWatcherTarget-Rich Environment for Duplication Report
The annual GAO report on duplication in federal spending provides opportunities to increase efficiency in the federal government.
Letters to OfficialsCCAGW Joins Coalition Opposing Legislative and Federal Reserve Efforts to Expand the Durbin Amendment to Credit Cards
The Durbin Amendment would limit competition and choice in the debit and credit card marketplace.
Porker of the MonthCAGW Names Sen. Kirsten Gillibrand May 2021 Porker of the Month
Senator Kirsten Gillibrand is our May 2021 Porker of the Month for saying “paid leave, child care and caregiving” are all “infrastructure.”
PressCAGW Names Sen. Kirsten Gillibrand May 2021 Porker of the Month
Senator Kirsten Gillibrand is our May 2021 Porker of the Month for saying “paid leave, child care and caregiving” are all “infrastructure.”
The WasteWatcherRepublican Study Committee Budget Is Good News for Taxpayers
The RSC budget includes the elimination and consolidation of dozens of programs and agencies.
State ActionCCAGW Urges Maine Joint Health and Human Services Committee to Oppose LD 1550
CCAGW urges the Maine Joint Health and Human Services Committee to oppose a ban on flavored tobacco products.
State ActionCCAGW Urges the Colorado House Health and Insurance Committee to Oppose SB21-175
CCAGW urges the Colorado House Health and Insurance Committee to oppose pharmaceutical price controls legislation.
